Patents by Inventor Adam S. Duerfeldt

Adam S. Duerfeldt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Phenylquinoline compositions for treatment of ocular disorders and conditions
    Patent number: 11337968
    Abstract: Compositions containing a phenylquinoline derivative compound having peroxisome proliferator-activated receptor a (PPAR?) agonistic activity, and methods of their use in enhancing PPAR? activity in retinal cells, and in treating ocular disorders or conditions, such as but not limited to retinal inflammation, retinal neovascularization, retinal vascular leakage, retinopathy of prematurity, diabetic retinopathy, age-related macular degeneration, and diabetic macular edema are disclosed.
    Type: Grant
    Filed: April 28, 2017
    Date of Patent: May 24, 2022
    Assignee: The Board of Regents of the University of Oklahoma
    Inventors: Jian-xing Ma, Elizabeth Moran, Guotao Deng, Adam S. Duerfeldt
  • PHENYLQUINOLINE COMPOSITIONS FOR TREATMENT OF OCULAR DISORDERS AND CONDITIONS
    Publication number: 20190336491
    Abstract: Compositions containing a phenylquinoline derivative compound having peroxisome proliferator-activated receptor a (PPAR?) agonistic activity, and methods of their use in enhancing PPAR? activity in retinal cells, and in treating ocular disorders or conditions, such as but not limited to retinal inflammation, retinal neovascularization, retinal vascular leakage, retinopathy of prematurity, diabetic retinopathy, age-related macular degeneration, and diabetic macular edema are disclosed.
    Type: Application
    Filed: April 28, 2017
    Publication date: November 7, 2019
    Inventors: Jian-xing Ma, Elizabeth Moran, Guotao Deng, Adam S. Duerfeldt
  • GRP94 inhibitors
    Patent number: 8685966
    Abstract: The present disclosure provides a series of compounds which exhibit isoform selective inhibition of GRP94, a homologue of Hsp90 that is localized to the endoplasmic recticulum. Through GRP94 inhibition, these compounds are likely to manifest anti-cancer, anti-inflammatory, anti-metastasis, and immunosuppressive activities, as well as utility in the treatment of neurodegenerative diseases, and diabetes.
    Type: Grant
    Filed: April 6, 2012
    Date of Patent: April 1, 2014
    Assignee: University of Kansas
    Inventors: Brian S. J. Blagg, Adam S. Duerfeldt
  • GRP94 INHIBITORS
    Publication number: 20130109684
    Abstract: The present disclosure provides a series of compounds which exhibit isoform selective inhibition of GRP94, a homologue of Hsp90 that is localized to the endoplasmic recticulum. Through GRP94 inhibition, these compounds are likely to manifest anti-cancer, anti-inflammatory, anti-metastasis, and immunosuppressive activities, as well as utility in the treatment of neurodegenerative diseases, and diabetes.
    Type: Application
    Filed: April 6, 2012
    Publication date: May 2, 2013
    Applicant: University of Kansas
    Inventors: Brian S.J. Blagg, Adam S. Duerfeldt